Ebola virus disease – Democratic Republic of the Congo :: Situation report on the Ebola outbreak in North Kivu :: WHO provides medicines and equipment for Ebola preparedness and control of Malaria & Neglected Tropical Diseases in Tanzania :: Uganda heightens Ebola preparedness response :: Congo: 2 Who Received Experimental Ebola Treatment Recover

Milestones :: Perspectives
 
Ebola – DRC

WHO
Ebola virus disease – Democratic Republic of the Congo
Disease outbreak news
24 August 2018
Since the last Disease Outbreak News on 17 August 2018, 25 additional cases have been laboratory confirmed for Ebola virus disease (EVD) in the Democratic Republic of the Congo. These new confirmed cases have been reported in Beni, Oicha and Mabalako health zones (North Kivu province) and Mandima health zone (Ituri Province). However, all exposures and transmission events, to date, have been linked back to the outbreak epi-centre, Mabalako. Beyond the EVD outbreak, the Democratic Republic of the Congo is in a complex humanitarian crisis and is experiencing several other concurrent epidemics.

As of 22 August 2018, a total of 103 EVD cases (76 confirmed and 27 probable) including 63 deaths (36 confirmed and 27 probable) have been reported1 in five health zones in North Kivu (Beni, Butembo, Oicha, Mabalako, Musienene) and one health zone in Ituri (Mandima) (Figure 1). The majority of cases (62 confirmed and 21 probable) have been reported from Mabalako in Mabalako Health Zone (Figure 2). As of 22 August, six new suspected cases from Mabalako (n=3) and Beni (n=3) are pending laboratory testing to confirm or exclude EVD. A total of 88 confirmed and probable cases have age and sex reported. As of 19 August, the median age was 32 years (age range: 0-74), with the age group 30-39 accounting for 28% (25/88) of cases. Fifty eight percent (51/88) of all cases were female (Figure 3).

Fourteen cases have been reported among health workers, of which 13 were laboratory confirmed; one has died. Many of these health care workers were likely infected in clinics before the declaration of the outbreak, not in Ebola treatment centres (ETCs). WHO and partners are working with health workers and communities to increase awareness on infection, prevention and control (IPC) measures, as well as vaccinate those at risk of infection.

The MoH, WHO and partners continue to systematically monitor and rapidly investigate all alerts in all provinces of the Democratic Republic of Congo, and in neighbouring countries2. Alerts in several provinces of the Democratic Republic of Congo as well as in Uganda, Rwanda, and the Central African Republic have been investigated; EVD has been ruled out in all alert events to date.
 
 
Situation report on the Ebola outbreak in North Kivu  22 August 2018
[Excerpt]
Case management
…The Ethics Committee in the Democratic Republic of the Congo has approved the use of four additional experimental therapeutics, namely: ZMapp, Remdesivir, Favipiravir, and Regn3450 – 3471 – 3479, to be used by the ETC medical and research teams. This is in addition to the mAb114, approved earlier….

WHO provides medicines and equipment for Ebola preparedness and control of Malaria & Neglected Tropical Diseases in Tanzania   24 August 2018

Uganda heightens Ebola preparedness response   23 August 2018

New York Times
http://www.nytimes.com/
Accessed 25 Aug 2018
Congo: 2 Who Received Experimental Ebola Treatment Recover
By The Associated Press
Aug. 25, 2018
KINSHASA, Congo — Congo’s health ministry says two of the first 10 people to receive an experimental treatment for the Ebola virus in the latest outbreak have recovered, and monitoring could show what role the treatment played.
The head of the World Health Organization on Saturday congratulated Congo’s government for making several experimental treatments available in this Ebola outbreak, calling it “a global first, and a ray of hope for people with the disease.”
The two people received the mAb114 treatment isolated from a survivor of an Ebola outbreak in 1995. It was the first of five experimental treatments Congo approved for use in the outbreak that was declared on Aug. 1. The others are ZMapp, Remdesivir, Favipiravir and Regn3450 – 3471 – 3479…